|LS02||TUESDAY, 15 APRIL 2014||ROOM: 3
|Evidence Informed Decision Making in Achieving UHC:
the Role of Macro HTA
|Dr. Nick Drager
Honorary Professor, Senior Fellow, Global Health Programme, The Graduate Institute, Geneva
|Mr. Adrian Griffin
Vice President, HTA Policy, Johnson & Johnson
|Dr. Franz Pichler
Director, Global Public Policy, Eli Lilly and Company
|Dr. John-Arne Røttingen
Norwegian Knowledge Centre for the Health Services
|Dr. Eva Maria Ruiz de Castilla
Executive Director, Esperantra (NPO, Peru)
As a number of countries aspire to implement universal health coverage frameworks, many are looking at methods to best structure their health system to ensure citizens obtain the health services they need. Given cost constrained environments, many low and middle income countries have increasingly focused efforts on prioritization and determining value for investments in health. As such, a significant focus has turned towards the use of research evidence as a tool to support decision making. However, historically, this type of evidence has rarely been applied to support overall health system decision making. In the context of developed countries, a narrow interpretation has placed a significant emphasis on decisions related to coverage and reimbursement of healthcare technologies, such as medicines and diagnostics. 1 Healthcare technologies are only one of several inputs in the overall health system. The organization and delivery of a health care system is a complex matter, which requires a number of decisions regarding the resources necessary to ensure access to services, the mix of interventions required and the means to achieve optimal results.2 Limiting evidence based decision making to coverage decisions tends to obscure the potential role to apply to the overall health system as a whole, such as interventions that facilitate access, service delivery, and aim to improve quality of care.
Therefore, as countries embark towards universal health coverage, it is important that decisions related to coverage of health products and benefits packages are only one part of the discussion. Many low and middle income countries have extensive inefficiencies in their health systems, including issues related to service delivery, quality of care and treatment standards that transcend the need to focus specifically on coverage of health technologies to determine value for investments in health.
This session will explore the role of evidence informed decision making in achieving universal health coverage, looking specifically at the role of "macro" HTA as it is applied to overall health system efficiency and quality of care. This unique session will provide the audience with a view of different perspectives from various sectors in the healthcare space - patient, industry, academic and payer/NGO. Through live interaction, the audience will be able to participate and provide thought provoking questions/answers amongst the group to explore this innovative topic.
Nick Drager M.D., Ph.D
Honorary Professor, Senior Fellow, Global Health Programme, The Graduate Institute, Geneva
Former Director of the Department of Ethics, Equity, Trade and Human Rights and Senior Adviser in the Strategy Unit, Office of the Director-General at the World Health Organization- now is Honorary Professor, Global Health Policy, London School of Hygiene & Tropical Medicine; Professor of Practice, Public Policy and Global Health Diplomacy, McGill University; Adjunct Professor, Department of Epidemiology and Community Medicine, University of Ottawa; Adjunct Research Professor, Norman Paterson School of International Affairs, Ottawa; and Senior Fellow, Global Health Programme, The Graduate Institute, Geneva.
- Work focuses on current and emerging issues related to global health, in the areas of global health security/diplomacy/governance, foreign policy and international trade and health including intellectual property and health.
- Extensive experience working with senior officials in over 100 countries and major multilateral and bilateral development agencies in health policy development, health sector analysis, strategic planning and resource mobilization and allocation decisions and in providing strategic advice on health development negotiations and in conflict resolution.
- Deep experience in global health diplomacy and high-level negotiations on international health security and development issues.
- Represented WHO, serves as chair, keynote speaker at major international events and conferences; lectures and teaches at Universities in Europe, North America and Asia.
- Editor/author of books, papers and editorials in the area of global health; global health diplomacy; trade and health including IP; foreign policy and health. Has an M.D. from McGill University and a Ph.D. in Economics from Hautes Etudes Internationales, (the Graduate Institute) University of Geneva.
Adrian Griffin is Vice President, HTA & Market Access Policy at Johnson & Johnson. He has been involved in the fields of health economics, outcomes research, and reimbursement policy within the healthcare industry for 16 years, with experience across the pharmaceutical, medical device, and diagnostic sectors.
Mr Griffin graduated in Medicinal Chemistry from University College London, obtained a post-graduate teaching qualification from Oxford University, and spent several years teaching chemistry before joining the UK’s Medical Research Council. He then received his MSc in Health Economics at City University, London, before joining the healthcare industry. Mr Griffin has held positions at GlaxoSmithKline, Pharmacia, and most recently Johnson & Johnson, where he has been since 2003.
In addition to undertaking outcomes research from the industry perspective, Mr Griffin has also served as a ‘decision-maker’, on the NICE Technology Appraisal Committee, where he has been a committee member for 10 years. Mr Griffin is also active in numerous multi-stakeholder forums where key issues of HTA and access policy are debated and shaped, such as the HTAi Policy Forum, and initiatives that have brought regulators and HTA agencies together with companies, thus improving transparency and appreciation of different stakeholder perspectives.
Mr Griffin has contributed to several UK industry-government task-force and working groups, aimed at developing policy and processes to improve equitable access and uptake for patients to new innovations.
Within Europe, Mr Griffin has engaged through Company and Industry Association activities with EUnetHTA, with the aim of ensuring that what comes out of HTA collaboration across Europe is fit for purpose, with the ultimate aim of improving healthcare for patients.
Mr Griffin is currently on the Board of Directors of ISPOR, (the International Society for Pharmacoeconomics and Outcomes Research), and continues in his position as a member of the NICE Technology Appraisals Committee
Franz Pichler has been Director, Global Public Policy at Eli Lilly and Company since 2012. This role encompasses development of external policy positions; provision of strategic advice; and external engagement around policy-related issues. A key focus of the role relates to the European environment, in particular with regards to Health Technology Assessment (HTA) and market access. He represents Lilly on the EuropaBio HTA and Market Access Group and the EFPIA HTA Task Force Steering Committee. He participates in the EUnetHTA Stakeholder Advisory Groups related to relative effectiveness assessment and methodological guidelines development. He is co-chair of the Medicines Adaptive Pathways to Patients initiative and is a participant of the Innovative Medicines Initiative (IMI) project ‘Incorporating real-life clinical data into drug development’ (GetREAL). He was a founding member of the HTAi interest sub group on HTA-Regulatory Interactions which he currently chairs. Franz joined Lilly after serving as the manager of the HTA Programme at the Centre for Innovation in Regulatory Science (CIRS) – a non-profit, independent medicines policy and research think tank. Prior to joining CIRS, Franz worked for over 10 years in molecular biology with specialties in functional genomics, population genetics and bioinformatics. He obtained his BSC in biology and PhD in population genetics at the University of Auckland in 1997 and 2002 respectively.
John-Arne Røttingen is Director of the Division of Infectious Disease Control at the Norwegian Institute of Public Health; Professor of Health Policy at the Department of Health Management and Health Economics, Institute of Health and Society, Faculty of Medicine, University of Oslo; Visiting Professor at the Department of Global Health and Population, Harvard School of Public Health; and Institute Visiting Scholar at the Harvard Global Health Institute.
He is Associate Fellow at the Centre on Global Health Security, Chatham House; research associate of the European Observatory on Health Systems and Policies; Chair of the Board of the Alliance for Health Policy and Systems Research; member of the Scientific Oversight Group of the Institute for Health Metrics and Evaluation, University of Washington, Seattle; and member of the International Advisory Committee for the Global Burden of Disease study.
He has been Director General of the Norwegian Knowledge Centre for the Health Services; Oxford Scholar at Wadham College; and Fulbright Fellow at Harvard Kennedy School.
He received his MD and PhD from the University of Oslo, an MSc from Oxford University and an MPA from Harvard University.
Dr. Eva Maria Ruiz de Castilla is a co-founder and since 2006 Executive Director of ESPERANTRA, a not-for-profit cancer and chronic disease patient advocacy organization in Lima, Peru. Her work at Esperantra is to improve the quality of life of patients with chronic conditions, health promotion, and to advance the recognition of the rights of patients to achieve access to timely diagnosis, treatment, and follow-up care. She has been instrumental in a number of national initiatives focused on cancer, including the government’s Plan Esperanza launched in 2012 to provide basic cancer care coverage for the poorest and most vulnerable Peruvians.
In addition to her work with Esperantra, Dr Ruiz de Castilla consults part-time for various Peruvian ministries, including Health, Social Development, Housing, Women, and Water-Sanitation to help design and coordinate the country’s public-sector social assistance programs. From 2011 to 2012, Dr Ruiz de Castilla was Director General of the Peruvian Ministry of Health’s (MINSA) International Coordination office and before that served as MINSA’s Director General of Health Prevention and Promotion. She has in-depth experience working with donor country agencies and multilateral organizations such as the World Bank.
As a Board Member of the International Alliance of Patients’ Organizations (IAPO) since 2010, Dr Ruiz de Castilla has been a global leader in patient-based organizational capacity building and has led various workshops on patient empowerment and networking. Her experience and involvement with building the capacity of civil society organizations focused on cancer in Peru earned her the American Cancer Society’s “Excelencia Latina 2009” Award. In 2011, Dr Ruiz de Castilla was named a Global Cancer Ambassador by the American Cancer Society, and was invited by the World Health Organization to participate as a civil society representative during the UN High-Level Meeting on non-communicable diseases (NCDs).
Dr Ruiz de Castilla’s academic credentials include degrees in Industrial Engineering and a PhD in Economic Development at the EHESS in Paris, France, and in Political Science at the Sorbonne University Paris 1. In Europe, she consulted for the United Nations on food and agriculture issues for the southern common market (MERCOSUR). Dr Ruiz de Castilla has authored a number of publications and papers on social development, health, and citizen engagement, and has been invited to speak at more than 200 national and international congresses.